{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:36:56Z","timestamp":1785523016083,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Central Government Guides Local Science and Technology Development Fund Projects","award":["2025ZY01110"],"award-info":[{"award-number":["2025ZY01110"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2026ZD0558207"],"award-info":[{"award-number":["2026ZD0558207"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05301-2","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:04:46Z","timestamp":1785139486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between anti-PLA2R antibody status and clinical remission in primary membranous nephropathy: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"given":"Qing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qikai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yourou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"8","key":"5301_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7326\/0003-4819-116-8-672","volume":"116","author":"HA Austin 3rd","year":"1992","unstructured":"Austin HA 3rd, Antonovych TT, MacKay K et al (1992) Membranous nephropathy. Ann Intern Med 116(8):672\u2013682. https:\/\/doi.org\/10.7326\/0003-4819-116-8-672","journal-title":"Ann Intern Med"},{"issue":"1","key":"5301_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12951-024-02633-y","volume":"22","author":"L Wang","year":"2024","unstructured":"Wang L, Wang J, Xu A et al (2024) Future embracing: exosomes driving a revolutionary approach to the diagnosis and treatment of primary membranous nephropathy. J Nanobiotechnol 22(1):472. https:\/\/doi.org\/10.1186\/s12951-024-02633-y","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"5301_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha E, Reinhard L, Stahl RAK (2022) Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol 18(7):466\u2013478. https:\/\/doi.org\/10.1038\/s41581-022-00564-1","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"5301_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.kint.2019.10.009","volume":"97","author":"SB Ahmad","year":"2020","unstructured":"Ahmad SB, Appel GB (2020) Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int 97(1):29\u201331. https:\/\/doi.org\/10.1016\/j.kint.2019.10.009","journal-title":"Kidney Int"},{"issue":"10","key":"5301_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","volume":"21","author":"S Sethi","year":"2025","unstructured":"Sethi S, Fervenza FC (2025) Antigens in membranous nephropathy: discovery and clinical implications. Nat Rev Nephrol 21(10):653\u2013670. https:\/\/doi.org\/10.1038\/s41581-025-00980-z","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"5301_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG (2017) Primary membranous nephropathy. Clin J Am Soc Nephrol 12(6):983\u2013997. https:\/\/doi.org\/10.2215\/CJN.11761116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"5301_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","volume":"96","author":"AE van de Logt","year":"2019","unstructured":"van de Logt AE, Fresquet M, Wetzels JF et al (2019) The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int 96(6):1292\u20131302. https:\/\/doi.org\/10.1016\/j.kint.2019.07.014","journal-title":"Kidney Int"},{"issue":"4S","key":"5301_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"8","key":"5301_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck Jr","year":"2011","unstructured":"Beck LH Jr, Fervenza FC, Beck DM et al (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22(8):1543\u20131550. https:\/\/doi.org\/10.1681\/ASN.2010111125","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5301_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173201","volume":"12","author":"F Pourcine","year":"2017","unstructured":"Pourcine F, Dahan K, Mihout F et al (2017) Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS ONE 12(3):e0173201. https:\/\/doi.org\/10.1371\/journal.pone.0173201","journal-title":"PLoS ONE"},{"issue":"1","key":"5301_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1544-2","volume":"20","author":"Y Liang","year":"2019","unstructured":"Liang Y, Wan J, Chen Y et al (2019) Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis. BMC Nephrol 20(1):360. https:\/\/doi.org\/10.1186\/s12882-019-1544-2","journal-title":"BMC Nephrol"},{"issue":"6","key":"5301_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","volume":"25","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Thiele I, Zahner G et al (2014) Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25(6):1357\u20131366. https:\/\/doi.org\/10.1681\/ASN.2013040430","journal-title":"J Am Soc Nephrol"},{"key":"5301_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"4","key":"5301_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL et al (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158(4):280\u2013286. https:\/\/doi.org\/10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"issue":"6","key":"5301_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","volume":"144","author":"JA Hayden","year":"2006","unstructured":"Hayden JA, C\u00f4t\u00e9 P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144(6):427\u2013437. https:\/\/doi.org\/10.7326\/0003-4819-144-6-200603210-00010","journal-title":"Ann Intern Med"},{"issue":"12","key":"5301_CR16","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s10157-025-02731-7","volume":"29","author":"D Wu","year":"2025","unstructured":"Wu D, Liu W, Su Z et al (2025) Clinical outcomes of immunosuppressive therapy in patients with seronegative anti-PLA2R antibodies and PLA2R-related membranous nephropathy. Clin Exp Nephrol 29(12):1783\u20131795. https:\/\/doi.org\/10.1007\/s10157-025-02731-7","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"5301_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.nefro.2015.05.026","volume":"35","author":"E Jatem Escalante","year":"2015","unstructured":"Jatem Escalante E, Segarra Medrano A, Carnicer C\u00e1ceres C et al (2015) Clinical features, course and prognosis of primary membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Nefrologia 35(5):479\u2013486. https:\/\/doi.org\/10.1016\/j.nefro.2015.05.026","journal-title":"Nefrologia"},{"issue":"10","key":"5301_CR18","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1681\/ASN.2015080953","volume":"27","author":"HZ Qin","year":"2016","unstructured":"Qin HZ, Zhang MC, Le WB et al (2016) Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol 27(10):3195\u20133203. https:\/\/doi.org\/10.1681\/ASN.2015080953","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5301_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12882-017-0636-0","volume":"18","author":"J Wang","year":"2017","unstructured":"Wang J, Xie Q, Sun Z et al (2017) Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R-associated primary membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol 18(1):227. https:\/\/doi.org\/10.1186\/s12882-017-0636-0","journal-title":"BMC Nephrol"},{"issue":"25","key":"5301_CR20","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.12659\/MSM.917732","volume":"9","author":"N Guo","year":"2019","unstructured":"Guo N, Cao Y, Dai H et al (2019) Anti-phospholipase A2 receptor (Anti-PLA2R) antibody in diagnosis and treatment of primary membranous nephropathy: a single-center observational study in China. Med Sci Monit 9(25):9364\u20139368. https:\/\/doi.org\/10.12659\/MSM.917732","journal-title":"Med Sci Monit"},{"issue":"16","key":"5301_CR21","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.2147\/JIR.S427045","volume":"22","author":"NQ Xie","year":"2023","unstructured":"Xie NQ, Zhang YL, Zheng ZL et al (2023) Association of M-type phospholipase A2 receptor deposition in kidney tissue with treatment outcomes in patients with primary membranous nephropathy. J Inflamm Res 22(16):6319\u20136328. https:\/\/doi.org\/10.2147\/JIR.S427045","journal-title":"J Inflamm Res"},{"issue":"8","key":"5301_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4103\/0366-6999.204096","volume":"130","author":"NX Xu","year":"2017","unstructured":"Xu NX, Xie QH, Sun ZX et al (2017) Renal phospholipase A2 receptor and the clinical features of primary membranous nephropathy. Chin Med J (Engl) 130(8):892\u2013898. https:\/\/doi.org\/10.4103\/0366-6999.204096","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"5301_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10157-014-1064-0","volume":"19","author":"N Hayashi","year":"2015","unstructured":"Hayashi N, Akiyama S, Okuyama H et al (2015) Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol 19(5):797\u2013803. https:\/\/doi.org\/10.1007\/s10157-014-1064-0","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"5301_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/0886022X.2020.1792315","volume":"42","author":"P Yin","year":"2020","unstructured":"Yin P, Wang J, Liang W et al (2020) Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study. Ren Fail 42(1):675\u2013683. https:\/\/doi.org\/10.1080\/0886022X.2020.1792315","journal-title":"Ren Fail"},{"issue":"10","key":"5301_CR25","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26(10):2545\u20132558. https:\/\/doi.org\/10.1681\/ASN.2014070640","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5301_CR26","doi-asserted-by":"publisher","first-page":"2297015","DOI":"10.1080\/0886022X.2023.2297015","volume":"46","author":"X Li","year":"2024","unstructured":"Li X, Shen Y, Li Y et al (2024) Clinicopathological characteristics and outcomes of PLA2R related primary membranous nephropathy in patients with seronegative PLA2R antibodies. Ren Fail 46(1):2297015. https:\/\/doi.org\/10.1080\/0886022X.2023.2297015","journal-title":"Ren Fail"},{"issue":"6","key":"5301_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000494662","volume":"48","author":"Z Qu","year":"2018","unstructured":"Qu Z, Zhang MF, Cui Z et al (2018) Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy. Am J Nephrol 48(6):438\u2013446. https:\/\/doi.org\/10.1159\/000494662","journal-title":"Am J Nephrol"},{"issue":"11","key":"5301_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"5301_CR29","unstructured":"Deeks JJ, Higgins JPT, Altman DG, et al. Chapter 10: Analysing data and undertaking meta\u2011analyses. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10#section-10-10-2"},{"issue":"2","key":"5301_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jrsm.11","volume":"1","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W, Cheung MW (2010) Outlier and influence diagnostics for meta-analysis. Res Synth Methods 1(2):112\u2013125. https:\/\/doi.org\/10.1002\/jrsm.11","journal-title":"Res Synth Methods"},{"issue":"1","key":"5301_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in primary membranous nephropathy. N Engl J Med 361(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"5301_CR32","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.nephro.2017.02.002","volume":"13","author":"K Dahan","year":"2017","unstructured":"Dahan K (2017) Traitement de la glom\u00e9rulon\u00e9phrite extramembraneuse [Membranous nephropathy: new insights in therapeutic approach]. Nephrol Ther 13(Suppl 1):S83\u2013S87. https:\/\/doi.org\/10.1016\/j.nephro.2017.02.002","journal-title":"Nephrol Ther"},{"issue":"6","key":"5301_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000494661","volume":"48","author":"JFM Wetzels","year":"2018","unstructured":"Wetzels JFM (2018) Antibodies against M-type phospholipase receptor and prediction of outcome in membranous nephropathy: we are not there yet. Am J Nephrol 48(6):434\u2013437. https:\/\/doi.org\/10.1159\/000494661","journal-title":"Am J Nephrol"},{"issue":"1","key":"5301_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ckj\/sfy079","volume":"12","author":"M Diaz","year":"2019","unstructured":"Diaz M, Agraz I, Soler MJ (2019) Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. Clin Kidney J 12(1):33\u201335. https:\/\/doi.org\/10.1093\/ckj\/sfy079","journal-title":"Clin Kidney J"},{"issue":"4","key":"5301_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062151","volume":"8","author":"YJ Oh","year":"2013","unstructured":"Oh YJ, Yang SH, Kim DK et al (2013) Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS ONE 8(4):e62151. https:\/\/doi.org\/10.1371\/journal.pone.0062151","journal-title":"PLoS ONE"},{"issue":"10","key":"5301_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110681","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Harendza S, Pinnschmidt H et al (2014) PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS ONE 9(10):e110681. https:\/\/doi.org\/10.1371\/journal.pone.0110681","journal-title":"PLoS ONE"},{"issue":"25","key":"5301_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011184","volume":"97","author":"XJ Zhou","year":"2018","unstructured":"Zhou XJ, Zhou FD, Wang SX et al (2018) A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: a long-term follow-up. Med (Baltimore) 97(25):e11184. https:\/\/doi.org\/10.1097\/MD.0000000000011184","journal-title":"Med (Baltimore)"},{"issue":"2","key":"5301_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251315913","volume":"53","author":"S Aydin","year":"2025","unstructured":"Aydin S, Emre E, Ugur K et al (2025) An overview of ELISA: a review and update on best laboratory practices for quantifying peptides and proteins in biological fluids. J Int Med Res 53(2):03000605251315913. https:\/\/doi.org\/10.1177\/03000605251315913","journal-title":"J Int Med Res"},{"key":"5301_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.peptides.2015.04.012","volume":"72","author":"S Aydin","year":"2015","unstructured":"Aydin S (2015) A short history, principles, and types of ELISA, and our laboratory experience with peptide\/protein analyses using ELISA. Peptides 72:4\u201315. https:\/\/doi.org\/10.1016\/j.peptides.2015.04.012","journal-title":"Peptides"},{"issue":"8","key":"5301_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104936","volume":"9","author":"Y Du","year":"2014","unstructured":"Du Y, Li J, He F et al (2014) The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS ONE 9(8):e104936. https:\/\/doi.org\/10.1371\/journal.pone.0104936","journal-title":"PLoS ONE"},{"issue":"8","key":"5301_CR41","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/ndt\/gfaf012","volume":"40","author":"O Ragy","year":"2025","unstructured":"Ragy O, Abass W, Kanigicherla DAK et al (2025) PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrol Dial Transplant 40(8):1458\u20131469. https:\/\/doi.org\/10.1093\/ndt\/gfaf012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"5301_CR42","doi-asserted-by":"publisher","first-page":"sfad191","DOI":"10.1093\/ckj\/sfad191","volume":"17","author":"B Wang","year":"2023","unstructured":"Wang B, Fu YQ, Xie LJ et al (2023) Measurement of urinary exosomal phospholipase A2 receptor is a sensitive method for diagnosis of PLA2R-associated membranous nephropathy. Clin Kidney J 17(1):sfad191. https:\/\/doi.org\/10.1093\/ckj\/sfad191","journal-title":"Clin Kidney J"},{"key":"5301_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/143274","volume":"2014","author":"A Behnert","year":"2014","unstructured":"Behnert A, Schiffer M, M\u00fcller-Deile J et al (2014) Antiphospholipase A\u2082 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Res 2014:143274. https:\/\/doi.org\/10.1155\/2014\/143274","journal-title":"J Immunol Res"},{"issue":"26","key":"5301_CR44","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1039\/d5ay00539f","volume":"17","author":"S Gao","year":"2025","unstructured":"Gao S, Deng Z, Kao S et al (2025) Development and application of an ultrasensitive immunoassay for antiphospholipase A2 receptor antibodies in the differential diagnosis of membranous nephropathy. Anal Methods 17(26):5473\u20135479. https:\/\/doi.org\/10.1039\/d5ay00539f","journal-title":"Anal Methods"},{"issue":"7","key":"5301_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2215\/CJN.11261114","volume":"10","author":"MM O'Shaughnessy","year":"2015","unstructured":"O\u2019Shaughnessy MM, Montez-Rath ME, Lafayette RA et al (2015) Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol 10(7):1170\u20131178. https:\/\/doi.org\/10.2215\/CJN.11261114","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"5301_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2215\/CJN.0000000000000070","volume":"18","author":"DP Chen","year":"2023","unstructured":"Chen DP, Henderson CD, Anguiano J et al (2023) Kidney disease progression in membranous nephropathy among Black participants with high-risk APOL1 genotype. Clin J Am Soc Nephrol 18(3):337\u2013343. https:\/\/doi.org\/10.2215\/CJN.0000000000000070","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"5301_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.19368\/j.cnki.2096-1782.2022.12.054","volume":"7","author":"X Qin","year":"2022","unstructured":"Qin X, Qi DL, Cen J et al (2022) Analysis of clinical and renal pathological characteristics of patients with idiopathic membranous nephropathy among different ethnic groups. Syst Med. 7(12):54\u201358. https:\/\/doi.org\/10.19368\/j.cnki.2096-1782.2022.12.054","journal-title":"Syst Med."},{"issue":"2","key":"5301_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati A, Mosconi L, Perna A et al (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329(2):85\u201389. https:\/\/doi.org\/10.1056\/NEJM199307083290203","journal-title":"N Engl J Med"},{"issue":"1","key":"5301_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1023\/a:1014404006045","volume":"33","author":"CA O'Callaghan","year":"2002","unstructured":"O\u2019Callaghan CA, Hicks J, Doll H et al (2002) Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol 33(1):157\u2013165. https:\/\/doi.org\/10.1023\/a:1014404006045","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"5301_CR50","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1681\/ASN.2015111262","volume":"28","author":"DC Cattran","year":"2017","unstructured":"Cattran DC, Kim ED, Reich H et al (2017) Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol 28(3):995\u20131003. https:\/\/doi.org\/10.1681\/ASN.2015111262","journal-title":"J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05301-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:21:59Z","timestamp":1785518519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05301-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":50,"alternative-id":["5301"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05301-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}